Fred Hutch opens dedicated research center in Seattle to test treatments for COVID-19 patients

The COVID-19 Clinical Research Center, foreground, in the Minor Building on Fred Hutchinson Cancer Research Center’s Seattle campus. (Fred Hutch Photo)

Seattle’s Fred Hutchinson Cancer Research Center is opening a new facility dedicated to testing treatments for people who have tested positive for COVID-19.

The COVID-19 Clinical Research Center, or CCRC is one of the first stand-alone facilities in the country designed for such work, according to Fred Hutch announcement on Monday. Located in the Minor Building on Fred Hutch’s South Lake Union campus, it was funded by philanthropic donations and public/private partnerships.

Scientists and clinicians will partner in the space with study volunteers, health care providers, research institutes, foundations and the biotech/pharmaceutical industry on Phase 1 through 3 clinical trials (observational and interventional) for COVID-19-positive participants.

Two studies are already underway:

  • A Phase 3 randomized, double-blind placebo-controlled trial to evaluate the efficacy and safety of remdesivir (GS-5734TM)
Read More

New research from Fred Hutch shows that an app can dramatically help smokers quit

Jonathan Bricker, professor at the Fred Hutchinson Cancer Research Center. (Fred Hutch Photo)

An app developed by the Fred Hutchinson Cancer Research Center is nearly four times more effective at helping smokers quit than the average success rate for those trying to kick cigarettes.

A clinical trial of 2,415 adult smokers nationwide found that 28% of participants using the Hutch’s iCanQuit app were able to quit after 12 months. The typical rate of smoking cessation in the U.S. is 7.5%, according to federal data from the Centers for Disease Control and Prevention.

The Fred Hutch study is one of the largest, most rigorous randomized trials to test both the performance of a mobile health therapy and evaluate the performance of an intervention approach known Acceptance and Commitment Therapy (ACT), said professor Jonathan Bricker, the study lead.

“We have the evidence of efficacy,” Bricker said. “Now we can look at how

Read More